MSDLLCpapers · dom-muston · Jan 6, 2026 · Jan 6, 2026 · Jan 6, 2026 · Jan 6, 2026
diff --git a/DESCRIPTION b/DESCRIPTION
@@ -1,11 +1,11 @@
 Package: dynamicpv
-Title: Evaluates Present Values and Cost-Effectiveness With Dynamic Pricing And Uptake
+Title: Evaluates Present Values and Cost-Effectiveness with Dynamic Pricing and Uptake
 Version: 0.4.0
 Authors@R: c(
     person("Dominic", "Muston", , "dominic.muston@msd.com", role = c("aut", "cre"),
            comment = c(ORCID = "0000-0003-4876-7940")),
-      person("John", "Blischak", role = c("ctb"),
-             comment = c(ORCID = "0000-0003-2634-9879")),
+    person("John", "Blischak", role = c("ctb"),
+           comment = c(ORCID = "0000-0003-2634-9879")),
     person("Merck & Co., Inc., Rahway, NJ, USA and its affiliates", role = c("cph", "fnd"))
     )
 Description: Evaluates present values and cost-effectiveness with dynamic pricing and uptake.
@@ -15,6 +15,8 @@ BugReports: https://github.com/MSDLLCpapers/dynamicpv/issues
 Encoding: UTF-8
 Roxygen: list(markdown = TRUE)
 RoxygenNote: 7.3.3
+Depends:
+    R (>= 4.1.0)
 Imports: 
     dplyr,
     readr,
@@ -32,7 +34,5 @@ Suggests:
     testthat (>= 3.0.0),
     usethis
 Config/testthat/edition: 3
-Depends: 
-    R (>= 3.5)
 LazyData: true
 VignetteBuilder: knitr
diff --git a/LICENSES-THIRD-PARTY.md b/LICENSES-THIRD-PARTY.md
@@ -1,9 +1,9 @@
-dynacem uses third-party R packages which may be distributed under different
+dynamicpv uses third-party R packages which may be distributed under different
 licenses. We have listed all of these third party packages and their licenses
 below. However, the most up-to-date information can be found via inspecting
 the Imports field in the DESCRIPTION file.
 
-You must agree to the terms of these licenses, in addition to the dynacem
+You must agree to the terms of these licenses, in addition to the dynamicpv
 source code license, in order to use this software.
 
 --------------------------------------------------
@@ -16,4 +16,4 @@ source code license, in order to use this software.
 * purrr - https://purrr.tidyverse.org/LICENSE.html
 * readr - https://readr.tidyverse.org/LICENSE.html
 * rlang - https://rlang.r-lib.org/LICENSE.html
-* tidyr - https://tidyr.tidyverse.org/LICENSE.html
+* tidyr - https://tidyr.tidyverse.org/LICENSE.html
diff --git a/R/data.R b/R/data.R
@@ -1,9 +1,9 @@
 #  Copyright (c) 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
 #  All rights reserved.
 #
-#  This file is part of the dynacem program.
+#  This file is part of the dynamicpv program.
 #
-#  dynacem is free software: you can redistribute it and/or modify
+#  dynamicpv is free software: you can redistribute it and/or modify
 #  it under the terms of the GNU General Public License as published by
 #  the Free Software Foundation, either version 3 of the License, or
 #  (at your option) any later version.
@@ -25,4 +25,4 @@
 #' @format ## `oncpsm`
 #' A heemod object
 #' @source Created based on assumptions.
-"oncpsm"
+"oncpsm"
diff --git a/R/dynamic.R b/R/dynamic.R
@@ -1,9 +1,9 @@
 #  Copyright (c) 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
 #  All rights reserved.
 #
-#  This file is part of the dynacem program.
+#  This file is part of the dynamicpv program.
 #
-#  dynacem is free software: you can redistribute it and/or modify
+#  dynamicpv is free software: you can redistribute it and/or modify
 #  it under the terms of the GNU General Public License as published by
 #  the Free Software Foundation, either version 3 of the License, or
 #  (at your option) any later version.

diff --git a/R/extract.R b/R/extract.R
@@ -1,9 +1,9 @@
 #  Copyright (c) 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
 #  All rights reserved.
 #
-#  This file is part of the dynacem program.
+#  This file is part of the dynamicpv program.
 #
-#  dynacem is free software: you can redistribute it and/or modify
+#  dynamicpv is free software: you can redistribute it and/or modify
 #  it under the terms of the GNU General Public License as published by
 #  the Free Software Foundation, either version 3 of the License, or
 #  (at your option) any later version.

diff --git a/R/future.R b/R/future.R
@@ -1,9 +1,9 @@
 #  Copyright (c) 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
 #  All rights reserved.
 #
-#  This file is part of the dynacem program.
+#  This file is part of the dynamicpv program.
 #
-#  dynacem is free software: you can redistribute it and/or modify
+#  dynamicpv is free software: you can redistribute it and/or modify
 #  it under the terms of the GNU General Public License as published by
 #  the Free Software Foundation, either version 3 of the License, or
 #  (at your option) any later version.

diff --git a/R/oop.R b/R/oop.R
@@ -1,9 +1,9 @@
 #  Copyright (c) 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
 #  All rights reserved.
 #
-#  This file is part of the dynacem program.
+#  This file is part of the dynamicpv program.
 #
-#  dynacem is free software: you can redistribute it and/or modify
+#  dynamicpv is free software: you can redistribute it and/or modify
 #  it under the terms of the GNU General Public License as published by
 #  the Free Software Foundation, either version 3 of the License, or
 #  (at your option) any later version.

diff --git a/README.Rmd b/README.Rmd
@@ -38,7 +38,7 @@ install.packages("devtools")
 pak::pak("MSDLLCpapers/dynamicpv")
 ```
 
-Note that the above does not install vignettes. Vignettes may be viewed on the [package website](https://msdllcpapers.github.io/dynacem) or by instead running the following.
+Note that the above does not install vignettes. Vignettes may be viewed on the [package website](https://msdllcpapers.github.io/dynamicpv/) or by instead running the following.
 
 ```{r instal2}
 #| eval: false

diff --git a/README.md b/README.md
@@ -40,8 +40,8 @@ pak::pak("MSDLLCpapers/dynamicpv")
 ```
 
 Note that the above does not install vignettes. Vignettes may be viewed
-on the [package website](https://msdllcpapers.github.io/dynacem) or by
-instead running the following.
+on the [package website](https://msdllcpapers.github.io/dynamicpv/) or
+by instead running the following.
 
 ``` r
 devtools::install_github("MSDLLCpapers/dynamicpv", build_vignettes=TRUE)

diff --git a/_pkgdown.yml b/_pkgdown.yml
@@ -1,4 +1,4 @@
-url: https://MSDLLCpapers.github.io/dynacem/
+url: https://MSDLLCpapers.github.io/dynamicpv/
 template:
   bootstrap: 5
   math-rendering: mathjax

diff --git a/data-raw/oncpsm.R b/data-raw/oncpsm.R
@@ -1,9 +1,9 @@
 #  Copyright (c) 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
 #  All rights reserved.
 #
-#  This file is part of the dynacem program.
+#  This file is part of the dynamicpv program.
 #
-#  dynacem is free software: you can redistribute it and/or modify
+#  dynamicpv is free software: you can redistribute it and/or modify
 #  it under the terms of the GNU General Public License as published by
 #  the Free Software Foundation, either version 3 of the License, or
 #  (at your option) any later version.

diff --git a/man/dynamicpv-package.Rd b/man/dynamicpv-package.Rd
diff --git a/vignettes/bibliography.bib b/vignettes/bibliography.bib
@@ -115,7 +115,7 @@ @article{enright_2025
 	title = {Use of health technology assessments in specialty drug coverage decisions by {US} commercial health plans},
 	volume = {31},
 	issn = {2376-1032},
-	doi = {10.18553/jmcp.2025.31.3.289},
+	url = {https://www.jmcp.org/doi/10.18553/jmcp.2025.31.3.289},
 	abstract = {BACKGROUND: Health technology assessment (HTA) involves a formal review of the clinical, economic, and societal implications of health technologies. Internationally, HTA supports decisions regarding access to novel therapeutics. However, the role of HTA in the decision-making processes of US-based health care payers remains unclear.
 OBJECTIVE: To assess how frequently US commercial health plans reference HTAs in their specialty drug coverage policies.
 METHODS: Using the Tufts Medical Center Specialty Drug Evidence and Coverage database, we reviewed the evidence cited in the publicly available specialty drug coverage policies of 17 US commercial health plans. We assessed the frequency of HTA citations and characterized them by (1) country of origin, (2) publishing organization, (3) whether it addressed a treatment's cost-effectiveness, (4) disease category addressed, and (5) whether it assessed orphan or nonorphan treatments.
@@ -150,10 +150,10 @@ @article{espinosa_2024
 	pages = {797--804},
 }
 
-@misc{dynacem,
+@misc{dynamicpv,
   title        = {{dynamcem} - A package for {R} to evaluate cost-effectiveness models with dynamic pricing and uptake.},
   author       = {Merck {\& Co.}, {Inc.}},
-  url	= {https://github.com/MSDLLCpapers/dynacem},
+  url	= {https://github.com/MSDLLCpapers/dynamicpv},
   urldate      = {Accessed: 1 July 2025}
 }
 
@@ -240,7 +240,7 @@ @article{ispor_value_flower
 
 @article{laube_2024,
 	title = {Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland},
-	doi = {10.1001/jamahealthforum.2024.446},
+	doi = {10.1001/jamahealthforum.2024.4461},
 	language = {en},
 	journal = {JAMA Health Forum},
 	author = {Laube, Y. and Serra-Burriel, M. and Glaus, C. C. E. G. and Vokinger, K. N.},
@@ -464,4 +464,4 @@ @article{woods_2024
 	month = Jan,
 	year = {2024},
 	pages = {804--819},
-}
+}